Day: March 5, 2024

MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2023. Fourth Quarter 2023 HighlightsFourth quarter 2023 revenue of $20.3 million, a 12% increase as compared to the fourth quarter 2022 U.S. NeuroStar Advanced Therapy system revenue of $4.5 million, in the quarter, the Company shipped 59 systems Achieved record U.S. treatment session revenue of $14.9 million in the fourth quarter 2023 Local consumable treatment session revenue increased by over 33% versus the fourth quarter 2022 The...

– Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle – – Strengthened Balance Sheet with $345 Million Public Offering Extending Projected Cash Runway Through 2025 – WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights. “We’ve had an exciting start to 2024 highlighted by Dyne’s first clinical data demonstrating proof-of-concept in our DM1 and DMD programs...

Revenue growth accelerates in Q4 to drive record Total RevenueAchieves Profitability with Q4 GAAP Net Income of $0.2 Million andQ4 Adjusted EBITDA of $10.0 MillionResults outperform guidance across all metrics LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) — Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, today reported its financial results for the fourth quarter and full year ended December 31, 2023. “2023 was an extraordinary year for Dave, and our results are a testament to the dedication and hard work of our exceptional team. Focused execution of our growth strategy enabled us to surpass our operational and financial objectives, exceeding our updated annual guidance across all metrics, and achieving profitability much earlier than anticipated,” stated Jason Wilk, Founder...

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023. “Our two lead oncology candidates, CM24 and NT219, designed to overcome tumor immune evasion, made significant clinical progress over the past year in difficult to treat indications, positioning them well as potential second line treatments in pancreatic and head and neck cancer. The acquisition last year of our conditionally activated T cells and NK cell engagers platform strongly positions us with a very promising and...

Total revenues of $891.6 million, up 22.1% and System-wide sales of $1.1 billion, up 20.6% Same-restaurant sales growth of 7.6%* with positive same-restaurant traffic growth Income from operations margin of 4.7% and Restaurant level operating profit margin of 20.0% Net income of $25.4 million and Adjusted EBITDA of $99.5 million 51 system-wide restaurants opened across 19 statesBRADENTON, Fla., March 05, 2024 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the fourteen weeks ended December 31, 2023 (“Q4 2023”) and the 53-week fiscal year ended December 31, 2023 (“2023”) compared to the thirteen weeks ended December 25, 2022 (“Q4 2022”) and the 52-week fiscal year...

ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Results and Business HighlightsFourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022. The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the fourth quarter and grew mid-single digits versus the fourth quarter of 2022. The Company estimates that revenues from scheduled non-trauma procedures represented approximately half of total revenues during the fourth quarter and grew...

Fourth Quarter GAAP Earnings of $10.6m and Non-GAAP Earnings of $27.8m Full Year 2023 Revenues of $126.8m Increased Hash Rate to 7.4 EH/s in First Quarter 2024 and on track to reach 9.3 EH/s by end of Third Quarter 2024, with potential to grow to 25 EH/s by the end of 2025 NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced results for its fourth quarter and full year ended December 31, 2023, with an update on its operations and deployment strategy. “We are delighted to announce our fourth quarter 2023 results, which reflect our first full quarter in which all four of our data centers were operating at full capacity. We delivered a quarter with strong positive net income on both a GAAP and Non-GAAP basis. And while recent FASB accounting...

CICERO, Ill., March 05, 2024 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the fourth quarter and full-year 2023. FOURTH QUARTER 2023 RESULTS(As compared to the fourth quarter 2022)Total revenue of $46.6 million, +16.3% y/y Total gross profit of $7.0 million, +$4.5 million y/y Net income of $1.1 million, or $0.05 per diluted share Total non-GAAP adjusted EBITDA of $4.4 million, +$4.3 million y/y Total tower sections sold +37.5% y/y to 132 sections Ratio of net debt to trailing twelve-month non-GAAP adjusted EBITDA of 0.8x as of December 31, 2023FULL-YEAR 2023 RESULTS(As compared to the full-year 2022)Total revenue of $203.5 million, +15.1% y/y Total gross profit of $32.5 million,...